ROCKVILLE, MD and SHENZHEN, CHINA, August 24, 2026 – HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, will participate in the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany, from August 28 to 31. During the congress, Dr. Filip Surmont, Chief Medical Officer of the company, will deliver an oral presentation highlighting data from multiple studies of HTD1801 in CKM diseases and its potential as a multisystem CKM therapy.
HTD1801 is an oral anti-inflammatory metabolic modulator (AIMM) that exerts its biological activity through the AMPK–NLRP3 axis, and has demonstrated the potential to address interconnected metabolic, cardiovascular, inflammatory, renal abnormalities, as well as obesity, underlying CKM diseases. The oral presentation will highlight the development of HTD1801 in CKM diseases and its potential as a multisystem therapeutic approach.
Abstract Title: HTD1801 as a Multisystem Cardiovascular‑Kidney‑Metabolic Therapy in Type 2 Diabetes: Phase III SYMPHONY Trials Demonstrate Early CKM Risk Modification
Presentation Number: 86063
Presentation Date/Time: Friday, August 28, 2026, 8:15 a.m. CEST
Format: Oral Presentation
Speaker: Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics
About HTD1801
HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts its biological activity through the AMPK–NLRP3 axis, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (2511.HK) is an innovative biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across CKM diseases. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s National Major Science and Technology Project for Significant New Drug Development.
For more information, please visit www.hightidetx.com，Contact: pr@hightidetx.com